IP Library Granted Patent US 12,168,691
Granted Patent B2
US 12,168,691 · App. 17/058,414 · Granted Dec 17, 2024

VHS format bi-specific antibodies specific for HER2 and VEGF and use thereof

Inventors: Zhen Fan (Houston, TX); Yang Lu (Houston, TX); Songho Qiu (Houston, TX)
Assignee: Board of Regents, The University of Texas System
C07K16/2863A61K39/3955A61K45/06A61P35/04C07K16/22A61K2039/505A61K2039/545C07K2317/31C07K2317/622
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,168,691
App. No.
17/058,414
Granted
Dec 17, 2024
Kind
B2
Abstract

The present disclosure provides a bispecific antibody comprising an IgG linked to an scFv, wherein the VII domain of the IgG is linked to the VH domain of the scFv, the bispecific antibody binding a human vascular endothelial growth factor (VEGF) family protein and an epidermal growth factor receptor (EGFR) family protein. Further embodiments provide pharmaceutical compositions comprising the bispecific antibody of the embodiments and aspects thereof and a pharmaceutically acceptable carrier. Further embodiments provide various methods of treating cancer in a subject comprising administering a bispecific antibody of the embodiments and aspects thereof to the subject. A further embodiment provides a kit comprising the bispecific antibody.

Claims (4)

1. A bispecific antibody comprising an anti-human vascular endothelial growth factor (VEGF) IgG antibody linked to an anti-human epidermal growth factor receptor-2 (HER2) scFv, wherein the VH domain of the IgG antibody is linked to the VH domain of the scFv, wherein the bispecific antibody comprises a first domain comprising SEQ ID NO:3 and a second domain comprising SEQ ID NO:4.

2. A pharmaceutical composition comprising the bispecific antibody of claim 1 and a pharmaceutically acceptable carrier.

3. A method of treating cancer in a subject having a HER2-overexpressing cancer comprising administering the bispecific antibody of claim 1 to the subject.

4. The method of claim 3 , wherein the cancer is breast, head and neck, lung, colorectal, prostate, kidney, pancreas, ovary, brain or bladder cancer.

Assignments (2)
CONFIRMATORY LICENSE Recorded Oct 12, 2022
From: UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 061656/0810 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2021
From: FAN, ZHEN; LU, YANG; QIU, SONGBO
To: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 056067/0438 →
Continuity (2)
Provisional Application 62678733 · May 31, 2018
Related Publication 20210198370A1 · Jul 1, 2021